Publication
Abstract
Realization of part of clinical trial called: Randomized, double-masked, multicenter Phase IIIb clinical trial of 24 months, assessing the efficacy and safety of two treatment regimens intravitreal injections of ranibizumab 0.5 mg řízencýh by functional and / or anatomickách criteria in patients with neovascular, age-related macular degeneration (OCTAVE)